Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2021 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

Recently reported that ongoing DUPLEX Study of sparsentan in FSGS achieved interim proteinuria endpoint Preparations underway for meetings with regulatory agencies in first half of 2021 to discuss...
March 09, 2020 08:00 ET | Source: Retrophin, Inc.

Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety...